Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients

被引:1
|
作者
Tortosa-Carreres, Jordi [1 ,2 ,3 ]
Cubas-Nunez, Laura [3 ]
Quiroga-Varela, Ana [4 ,5 ]
Castillo-Villalba, Jessica [3 ,4 ,5 ]
Ramio-Torrenta, Lluis [4 ,5 ,6 ,7 ]
Piqueras, Monica [1 ,2 ,8 ]
Gasque-Rubio, Raquel [2 ,3 ]
Quintanilla-Bordas, Carlos [3 ,9 ]
Sanz, Maria Teresa [10 ]
Lucas, Celia [11 ]
Huertas-Pons, Joana Maria [4 ,5 ]
Miguela, Albert [4 ,5 ]
Casanova, Bonaventura [3 ,9 ]
Laiz-Marro, Begona [1 ]
Perez-Miralles, Francisco Carlos [3 ,9 ]
机构
[1] La Fe Univ & Polytech Hosp, Lab Dept, Valencia 46026, Spain
[2] Univ Valencia, Med Dept, Valencia 46010, Spain
[3] Hlth Res Inst La Fe IISLAFE, Neuroimmunol Unit, Valencia, Spain
[4] Dr Josep Trueta Univ Hosp, Neurol Dept, Girona Neuroimmumol & Multiple Sclerosis Unit, Girona, Spain
[5] Santa Caterina Hosp, Girona, Spain
[6] Girona Biomed Res Inst IDIBGI, Neurodegenerat & Neuroinflammat Res Grp, Girona, Spain
[7] Univ Girona, Med Sci Dept, Girona, Spain
[8] Hlth Res Inst La Fe IISLAFE, Resp Infect, Valencia, Spain
[9] La Fe Univ & Polytech Hosp, Neurol Dept, Valencia 46026, Spain
[10] Univ Valencia, Dept Didact Math, Valencia, Spain
[11] La Fe Univ & Polytech Hosp, Comp Syst, Valencia 46026, Spain
关键词
Multiple sclerosis; Prognosis; Free kappa light chains; Therapeutic failure;
D O I
10.1016/j.msard.2024.105734
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Our objective was to explore various biomarkers for predicting suboptimal responses to diseasemodifying treatments (DMTs) in patients with MS (pwMS).<br /> Methods: We conducted a longitudinal, bicentric study with pwMS stratified based on their DMTs responses. Treatment failure (TF) was defined as the onset of a second relapse, presence of two or more T2 new lesions, or disability progression independent of relapse during the follow-up period. We evaluated intrathecal synthesis (ITS) of IgG and IgM using OCB, linear indices, and Reibergrams. Free kappa light chains ITS was assessed using the linear index (FKLCi). NfL and GFAP in serum and CSF, and CHI3L1 in CSF were quantified. Quantitative variables were dichotomized based on the third quartile. Predictive efficacy was assessed through bivariate and multivariate analyses, adjusting for age, sex, EDSS, acute inflammatory activity (AI) -defined as the onset of a relapse or gadolinium-enhancing lesions within a 90-day window of lumbar puncture-, treatment modality, study center, and time from disease onset to treatment initiation. In case of collinearity, multiple models were generated or confounding variables were excluded if collinearity existed between them and the biomarker. The same methodology was used to investigate the predictive potential of various combinations of two biomarkers, based on whether any of them tested positive or exceeded the third quartile.<br /> Results: A total of 137 pwMS were included. FKLCi showed no differences based on AI, no correlation with EDSS and was significantly higher in pwMS with TF (p = 0.008). FKLCi>130 was associated with TF in bivariate analysis (Log-Rank p = 0.004). Due to collinearity between age and EDSS, two different models were generated with each of them and the rest of the confounding variables, in which FKLCi>130 showed a Hazard Ratio (HR) of 2.69 (CI: 1.35-5.4) and 2.67 (CI: 1.32-5.4), respectively. The combination of either FKLC or sNfL exceeding the third quartile was also significant in bivariate (Log-Rank p = 0.04) and multivariate (HR=3.1 (CI: 1.5-6.5)) analyses. However, when analyzed independently, sNfL did not show significance, and FKLCi mirrored the pattern obtained in the previous model (HR: 3.04; CI: 1.51-6.1). Treatment with highefficacy DMTs emerged as a protective factor in all models.<br /> Discussion: Our analysis and the fact that FKLCi is independent of EDSS and AI suggest that it might be a valuable parameter for discriminating aggressive phenotypes. We propose implementing high-efficacy drugs in pwMS with elevated FKLCi.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Influence of repeat intrathecal triamcinolone acetonid application on cerebrospinal fluid and serum biomarkers in multiple sclerosis patients
    Abu-Mugheisib, M.
    Petzold, A.
    Grossmann, A.
    Kamin, F.
    Koehler, W.
    Hoffmann, F.
    Faiss, J. H.
    Ringel, I.
    Benecke, R.
    Zettl, U. K.
    MULTIPLE SCLEROSIS JOURNAL, 2006, 12 : S103 - S103
  • [22] Calprotectin in the cerebrospinal fluid reflects disease activity in multiple sclerosis
    Berg-Hansen, P.
    Vandvik, B.
    Fagerhol, M.
    Holmoy, T.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S199 - S199
  • [23] Predictive value of cerebrospinal fluid biomarkers on optic coherence tomography outcomes in multiple sclerosis
    Capuano, R.
    Llufriu, S.
    Pulido Valdeolivas, I.
    Zubizarreta, I.
    Andorra, M.
    Alba, S.
    Sepulveda, M.
    Martinez-Heras, E.
    Solana, E.
    Lopez-Soley, E.
    Sola-Valls, N.
    Montejo, C.
    Blanco, Y.
    Fernandez Velasco, J. I.
    Gallo, A.
    Tedeschi, G.
    Saiz, A.
    Villoslada, P.
    Villar, M. L.
    Martinez-Lapiscina, E. H.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 264 - 265
  • [24] Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid
    Kaushik, Deepak K.
    Yong, Heather Y. F.
    Hahn, Jennifer N.
    Silva, Claudia
    Casha, Steven
    Hurlbert, R. John
    Jacques, Francois H.
    Lisak, Robert
    Khan, Omar
    Ionete, Carolina
    Larochelle, Catherine
    Prat, Alex
    Bar-Or, Amit
    Yong, V. Wee
    PLOS ONE, 2016, 11 (10):
  • [25] Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis
    Novakova, Lenka
    Axelsson, Markus
    Khademi, Mohsen
    Zetterberg, Henrik
    Blennow, Kaj
    Malmestrom, Clas
    Piehl, Fredrik
    Olsson, Tomas
    Lycke, Jan
    JOURNAL OF NEUROCHEMISTRY, 2017, 141 (02) : 296 - 304
  • [26] SERUM AND CEREBROSPINAL FLUID IMMUNOGLOBULINS IN MULTIPLE SCLEROSIS
    KOLAR, OJ
    ROSS, AT
    HERMAN, JT
    NEUROLOGY, 1970, 20 (11) : 1052 - &
  • [27] Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis
    Chowdhury, Soheli A.
    Lin, Jerry
    Sadiq, Saud A.
    ARCHIVES OF NEUROLOGY, 2008, 65 (02) : 232 - 235
  • [28] LYMPHOCYTE ACTIVATING FACTOR ACTIVITY IN THE SERUM AND CEREBROSPINAL-FLUID OF PATIENTS WITH MULTIPLE-SCLEROSIS
    DONATI, D
    ANNUNZIATA, P
    GUAZZI, GC
    BORASCHI, D
    TAGLIABUE, A
    ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1990, 11 (01): : 21 - 29
  • [29] Cerebrospinal fluid and serum chitotriosidase activity in patients with clinically isolated syndrome suggestive of multiple sclerosis
    Dujmovic, I.
    Mesaros, S.
    Sumarac, Z.
    Dackovic, J.
    Markov, M.
    Bogdanovic, M.
    Martinovic, V.
    Drulovic, J.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 297 - 297
  • [30] Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis
    Lycke, JN
    Karlsson, JE
    Andersen, O
    Rosengren, LE
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03): : 402 - 404